X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/13/2845328/0/en/Atsena-Therapeutics-Announces-Initiation-of-Dosing-in-Second-Cohort-of-Phase-I-II-Clinical-Trial-Evaluating-ATSN-201-Gene-Therapy-for-the-Treatment-of-X-linked-Retinoschisis-XLRS.html
https://www.globenewswire.com//news-release/2024/01/16/2809753/0/en/Atsena-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-from-FDA-for-ATSN-101-Gene-Therapy-for-GUCY2D-associated-Leber-Congenital-Amaurosis-LCA1.html
https://www.globenewswire.com//news-release/2023/12/04/2789910/0/en/Atsena-Therapeutics-Announces-Positive-12-month-Safety-and-Efficacy-Data-from-Ongoing-Phase-I-II-Clinical-Trial-of-ATSN-101-in-Patients-with-Leber-Congenital-Amaurosis-Caused-by-Bi.html
https://www.globenewswire.com//news-release/2023/11/14/2779951/0/en/Atsena-Therapeutics-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-ATSN-101-Gene-Therapy-for-GUCY2D-associated-Leber-Congenital-Amaurosis-LCA1.html
https://www.fiercebiotech.com/biotech/north-carolina-biotech-atsena-downsizes-save-money-retinal-program-testing-new-capsid
https://www.globenewswire.com/news-release/2023/08/28/2732497/0/en/Atsena-Therapeutics-Announces-First-Patient-Dosed-in-Phase-I-II-Clinical-Trial-of-ATSN-201-for-the-Treatment-of-X-linked-Retinoschisis.html
https://www.globenewswire.com/news-release/2023/05/01/2658197/0/en/Atsena-Therapeutics-Receives-FDA-Clearance-of-IND-Application-for-ATSN-201-an-Investigational-Gene-Therapy-for-the-Treatment-of-X-linked-Retinoschisis.html
https://www.globenewswire.com/news-release/2023/04/25/2653762/0/en/Atsena-Therapeutics-Announces-Positive-6-month-Data-from-Ongoing-Phase-I-II-Clinical-Trial-of-ATSN-101-in-Patients-with-Leber-Congenital-Amaurosis-Caused-by-Biallelic-Mutations-in-.html
https://www.globenewswire.com/news-release/2023/04/11/2644262/0/en/Atsena-Therapeutics-Announces-Six-Month-Data-from-Phase-I-II-Clinical-Trial-of-ATSN-101-to-be-Presented-at-ARVO-2023-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/02/08/2603828/0/en/Atsena-Therapeutics-to-Present-Positive-Interim-Encore-Data-from-the-Phase-I-II-Clinical-Trial-of-ATSN-101-for-the-Treatment-of-GUCY2D-associated-Leber-Congenital-Amaurosis-LCA1-at.html
Market Place
Share 
